Lv3
360 积分 2021-12-10 加入
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort
5天前
已完结
Combination Diagnostics: Adding Blood-Based ctDNA Screening to Low-Dose CT Imaging for Early Detection of Lung Cancer
5天前
已完结
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of EGFR mutated NSCLC patients developing leptomeningeal metastases: ORA-LM study
5天前
已完结
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation
5天前
已完结
Liquid biopsy for the management of NSCLC patients under osimertinib treatment
5天前
已完结
Emergence of Circulating Tumor DNA as a Precision Biomarker in Lung Cancer Radiation Oncology and Beyond
5天前
已关闭
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non–Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02
5天前
已完结
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
5天前
已完结
Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study
5天前
已完结
Current advances and future prospects of blood-based techniques for identifying benign and malignant pulmonary nodules
5天前
已完结
皖公网安备34019202002308
